Literature DB >> 31512285

Quality of life in prostate cancer patients receiving particle radiotherapy: A review of the literature.

Hidemasa Kawamura1,2, Nobuteru Kubo1,2, Hiro Sato1,2, Yuhei Miyasaka1, Hiroshi Matsui2,3, Kazuto Ito3, Kazuhiro Suzuki2,3, Tatsuya Ohno1,2.   

Abstract

Proton and carbon ion radiotherapy for the treatment of prostate cancer is associated with a lower incidence of adverse events than conventional radiotherapy. There are few reports on the quality of life of patients treated with particle therapy, and limited patient-reported outcomes. Analysis of quality of life is important for patients treated with radiotherapy alone or in combination with hormonal therapy, and long-term results, dose fractionation and costs need to be included in the analysis. This information might help both clinical decision-making and selection of appropriate treatments according to the individual needs of patients. This study reviews the literature on the quality of life and outcomes of patients treated with particle therapy, and discusses future directions.
© 2019 The Japanese Urological Association.

Entities:  

Keywords:  carbon ion radiotherapy; particle therapy; prostate cancer; proton therapy; quality of life

Mesh:

Year:  2019        PMID: 31512285     DOI: 10.1111/iju.14102

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  2 in total

1.  Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer.

Authors:  Takashi Iizumi; Hitoshi Ishikawa; Yuta Sekino; Keiichi Tanaka; Daichi Takizawa; Hirokazu Makishima; Haruko Numajiri; Masashi Mizumoto; Kei Nakai; Toshiyuki Okumura; Hideyuki Sakurai
Journal:  J Med Radiat Sci       Date:  2021-10-19

Review 2.  Immunomodulatory Effects of Radiotherapy.

Authors:  Sharda Kumari; Shibani Mukherjee; Debapriya Sinha; Salim Abdisalaam; Sunil Krishnan; Aroumougame Asaithamby
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.